Hyperparathyroidism of different genesis in young patients with Turner syndrome: case series and brief review

Hyperparathyroidism is a syndrome characterized by an excessive secretion of parathyroid hormone. Etiologically, hyperparathyroidism is subdivided into primary hyperparathyroidism, which develops as a result of parathyroid adenoma, carcinoma or hyperplasia, and secondary hyperparathyroidism, which happens as a compensatory response to a hypocalcemia caused by condition outside the parathyroid glands. Turner syndrome may also be accompanied by mineral metabolism disorders of various etiology. An association of hyperparathyroidism and Turner syndrome is interesting because of multifactorial impact on bone mineral density, but only few cases of such coexistence have been previously described in the literature. This article describes two patients with Turner syndrome and hyperparathyroidism of different etiology. Hyperparathyroidism, normocalcemia, vitamin D deficiency, osteoporosis, parathyroid tumors were found in both cases. In one case a number of assays was performed to confirm the patient’s normocalcemic primary hyperparathyroidism, and surgery was performed to achieve remission. In the second case, treatment of vitamin D deficiency resulted in normalization of serum concentration of parathormone, after which the patient was prescribed antiresorptive therapy. The pathogenetic association between Turner syndrome and hyperparathyroidism requires further investigation. Comprehensive approach to the diagnosis and treatment of mineral metabolism disorders are essential for patients with coexistence of these two diseases.

1. Endokrinologija: nacional’noe rukovodstvo. Ed by Dedov II, Melnichenko GA. Moscow: GEOTAR-Media, 2021. (in Russ).

2. Davydovich MG, Pavlov VN, Kataev VA, et al. Hyperparathyroidism: diagnosis and treatment. Bashkortostan Medical Journal. 2017; 12(4):70. (in Russ).

3. Fraser WD. Hyperparathyroidism. Lancet. 2009; 374(9684):145-158. doi: https://doi.org/10.1016/S0140-6736(09)60507-9

4. Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017; 28(1):1-19. doi: https://doi.org/10.1007/S00198-016-3716-2

5. Bhadada SK, Arya AK, Mukhopadhyay S, et al. Primary hyperparathyroidism: insights from the Indian PHPT registry. J Bone Miner Metab. 2018; 36(2):238-245. doi: https://doi.org/10.1007/S00774-017-0833-8

6. Mokrysheva NG, Mirnaya SS, Dobreva EA, et al. Primary hyperparathyroidism in Russia according to the registry. Problems of Endocrinology. 2019; 65(5):300-310 (in Russ.) doi: https://doi.org/10.14341/PROBL10126-7792

7. Arya AK, Bhadada SK, Kumari P, et al. Differences in Primary Hyperparathyroidism Between Pre- and Postmenopausal Women in India. Endocr Pract. 2021; 27(7):710-715. doi: https://doi.org/10.1016/J.EPRAC.2020.12.012

8. Haglund F, Ma R, Huss M, et al. Evidence of a functional estrogen receptor in parathyroid adenomas. J Clin Endocrinol Metab. 2012; 97(12):4631-4639. doi: https://doi.org/10.1210/JC.2012-2484

9. Karaseva EV, Eremkina AK, Elfimova AR, et al. The short test with active metabolites of vitamin D in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment. Profil Meditsina. 2022; 25(6):68-74. (in Russ.) doi: https://doi.org/10.17116/PROFMED20222506168

10. Pamputis SN, Lopatnicova EN. Differential diagnostics of normocalcemic hyperparathyrosys with use of diagnostic test with alfa-calcidol. Tavricheskii mediko-biologicheskii vestnik. 2017; 20(3-2):205-211. (in Russ.)

11. Dedov II, Melnichenko GA, Mokrysheva NG, et al. Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients. Endocrine Surgery. 2022; 16(4):5-54. (In Russ.) doi: https://doi.org/10.14341/SERG12790

12. Mokrysheva NG. Okoloshhitovidnye zhelezy. Pervichnyj giperparatireoz. Moscow: Medicinskoe informacionnoe agentstvo; 2019. (in Russ.)

13. Ibarra-Ramírez M, Martínez-de-Villarreal LE. Clinical and genetic aspects of Turner’s syndrome. Med Univ. 2016; 18(70):42-48. doi: https://doi.org/10.1016/J.RMU.2016.03.003

14. McNamara LM. Osteocytes and Estrogen Deficiency. Curr Osteoporos Rep. 2021; 19(6):592-603. doi: https://doi.org/10.1007/S11914-021-00702-X

15. Cheng CH, Chen LR, Chen KH. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Int J Mol Sci 2022; 23(3):1376. doi: https://doi.org/10.3390/IJMS23031376

16. Dragun SA, Semicheva TV, Andreeva EN. Sostoyanie mineral’noy plotnosti kostnoy tkani i kostnogo metabolizma pri sindrome shereshevskogo-ternera. Obzor literatury. Osteoporosis and Bone Diseases. 2005; 8(2):44-48. (In Russ.) doi: https://doi.org/10.14341/OSTEO2005244-48

17. Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017; 177(3):G1-G70. doi: https://doi.org/10.1530/EJE-17-0430

18. Faienza MF, Ventura A, Colucci S, et al. Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies. Front Endocrinol. 2016; 7:34. doi: https://doi.org/10.3389/FENDO.2016.00034

19. Oliveira CS, Alves C. The role of the SHOX gene in the pathophysiology of Turner syndrome. Endocrinol Nutr. 2011; 58(8):433-442. doi: https://doi.org/10.1016/J.ENDONU.2011.06.005

20. Landin-Wilhelmsen K, Bryman I, Windh M, et al. Osteoporosis and fractures in Turner syndrome–importance of growth promoting and oestrogen therapy. Clin Endocrinol. 1999; 51(4):497-502. doi: https://doi.org/10.1046/J.1365-2265.1999.00841.X

21. Gravholt CH, Lauridsen AL, Brixen K, et al. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002; 87(6):2798-2808. doi: https://doi.org/10.1210/JCEM.87.6.8598

22. López MP, Miras M, Silvano L, et al. Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome. J Pediatr Endocrinol Metab. 2011; 24(5-6):307-312. doi: https://doi.org/10.1515/JPEM.2011.047

23. Santos LO, Laranjeira R, Borborema MEB d. A, et al. Vitamin D receptor (VDR) gene polymorphisms and expression profile influence upon the immunological imbalance in Turner syndrome. J Endocrinol Invest. 2020; 43(4):505-513. doi: https://doi.org/10.1007/S40618-019-01135-1

24. Saggese G, Federico G, Bertelloni S, et al. Mineral metabolism in Turner’s syndrome: evidence for impaired renal vitamin D metabolism and normal osteoblast function. J Clin Endocrinol Metab. 1992; 75(4):998-1001. doi: https://doi.org/10.1210/JCEM.75.4.1400894

25. Brot C, Vestergaard P, Kolthoff N, et al. Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr. 2001; 86(S1):S97-S103. doi: https://doi.org/10.1079/BJN2001345

26. Shah S, Nguyen HH, Vincent AJ. Care of the adult woman with Turner syndrome. Climacteric. 2018; 21(5):428-436. doi: https://doi.org/10.1080/13697137.2018.1476969

27. Agarwal K, Cherian KE, Abraham D, et al. Turner syndrome with primary hyperparathyroidism and meningioma: A rare association. Indian Journal of Endocrinology & Metabolism Case Reports. 2023; 1(1):24-27. doi: https://doi.org/10.4103/ijemcr.ijemcr_10_22

28. Shirzad N, Tehrani MR, Soltani A. A rare association of hyperparathyroidism and Turner’s syndrome - a case report. Endokrynol Pol. 2008; 59(3):232-4

29. Francois I, Proesmans W, De Zegher F. Case of the month: A girl with Ullrich-Turner syndrome, nephrolithiasis and hypercalcaemia. Eur J Pediatr. 1996; 155(7):615-616. doi: https://doi.org/10.1007/BF01957917/METRICS

30. Paul TV, Dinakar J, Thomas N, et al. A Case of Turner Syndrome with Hyperparathyroidism in an Adult. Ear, Nose & Throat Journal. 2008; 87(2):110-112. doi: https://doi.org/10.1177/014556130808700215

31. Kishida M, Otsuka F, Mimura Y, et al. A Lethal Complication, Acute Necrotizing Pancreatitis, of Turner’s Syndrome with Primary Hyperparathyroidism. Endocr J. 2003; 50(6):835-836. doi: https://doi.org/10.1507/ENDOCRJ.50.835

32. Sleiman I, Godi D, Villanacci V, et al. Osteitis fibrosa cystica, coeliac disease and Turner syndrome: A case report. Dig Liver Dis. 2004; 36(7):486-488. doi: https://doi.org/10.1016/J.DLD.2004.03.004

33. Park J, Kim YM, Choi JH, et al. Turner syndrome with primary hyperparathyroidism. Ann Pediatr Endocrinol Metab. 2013; 18(2):85-89. doi: https://doi.org/10.6065/APEM.2013.18.2.85

34. Dorado AE, Hensley G, Castleman B. Water clear cell hyperplasia of parathyroid: autopsy report of a case with supernumerary glands. Cancer. 1976; 38(4):1676-1683. doi: https://doi.org/10.1002/1097-0142

35. Nagaki S, Tachikawa E, Kodama H, et al. A case of Turner’s syndrome with Graves’ disease and primary hyperparathyroidism. SAGE Open Med Case Reports. 2021; 9. doi: https://doi.org/10.1177/2050313X211059002

36. Siller AF, Shimony A, Shinawi M, et al. Inherited Deletion of 1q, Hyperparathyroidism and Signs of Y-chromosomal Influence in a Patient with Turner Syndrome. J Clin Res Pediatr Endocrinol. 2019; 11(1):88-93. doi: https://doi.org/10.4274/JCRPE.GALENOS.2018.2018.0005

37. Chen JF, Chen JY, Huang HS. Primary hyperparathyroidism with parathyroid adenocarcinoma in a patient with Turner’s syndrome complicated with thyrotoxicosis. Chang yi xue za zhi. 1993; 16(2):133-139

38. Mokrysheva NG, Mirnaya SS, Dobreva EA, Primary hyperparathyroidism in Russia according to the registry. Problems of Endocrinology. 2019; 65(5):300-310. (in Russ.) doi: https://doi.org/10.14341/probl10126

39. Castellano E, Attanasio R, Boriano A, et al. Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status. J Clin Endocrinol Metab. 2017; 102(11):4148-4152. doi: https://doi.org/10.1210/JC.2017-01080

40. Wermers RA, Khosla S, Atkinson EJ, et al. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997; 126(6):433-440. doi: https://doi.org/10.7326/0003-4819-126-6-199703150-00003

41. Greenberg C, Kukreja SC, Bowser EN, et al. Parathyroid hormone secretion: Effect of estradiol and progesterone. Metab — Clin Exp. 1987; 36(2):151-154. doi: https://doi.org/10.1016/0026-0495(87)90009-6

42. Gallagher JC, Riggs BL, Deluca HF. Effect of Estrogen on Calcium Absorption and Serum Vitamin D Metabolites in Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 1980; 51(6):1359-1364. doi: https://doi.org/10.1210/JCEM-51-6-1359

43. Baran DT, Whyte MP, Haussler MR, et al. Effect of the Menstrual Cycle on Calcium-Regulating Hormones in the Normal Young Woman. J Clin Endocrinol Metab. 1980; 50(2):377-379. doi: https://doi.org/10.1210/JCEM-50-2-377

44. Prince RL, Maclaughlin DT, Gaz RD, et al. Lack of Evidence for Estrogen Receptors in Human and Bovine Parathyroid Tissue. J Clin Endocrinol Metab. 1991; 72(6):1226-1228. doi: https://doi.org/10.1210/JCEM-72-6-1226

45. Haglund F, Rosin G, Nilsson IL, et al. Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight. Endocr Connect. 2015; 4(1):76-85. doi: https://doi.org/10.1530/EC-14-0109

46. Vaira V, Verdelli C, Forno I, et al. MicroRNAs in parathyroid physiopathology. Mol Cell Endocrinol. 2017; 456:9-15. doi: https://doi.org/10.1016/J.MCE.2016.10.035

47. Yavropoulou MP, Poulios C, Michalopoulos N, et al. A Role for Circular Non-Coding RNAs in the Pathogenesis of Sporadic Parathyroid Adenomas and the Impact of Gender-Specific Epigenetic Regulation. Cells. 2018; 8(1):15. doi: https://doi.org/10.3390/CELLS8010015